JAVELIN Merkel 200: Results of Phase II Study for Merkel Cell Carcinoma

JAVELIN Merkel 200: Results of Phase II Study for Merkel Cell Carcinoma

User Photo
aacr2017

3 years
1,872 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Howard L. Kaufman, MD, FACS of Rutgers Cancer Institute of New Jersey gives an overview of his current research, a phase II study which involved a newly FDA-approved drug, avelumab, in patients with merkel cell carcinoma. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Up Next Autoplay
User Photo